Advertisement

Vaginal Suppositories with siRNA and Paclitaxel-Incorporated Solid Lipid Nanoparticles for Cervical Cancer: Preparation and In Vitro Evaluation

  • Gülay BüyükköroğluEmail author
  • Behiye Şenel
  • Evrim Yenilmez
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1974)

Abstract

The objective of this study is to prepare vaginal suppository containing chemotherapeutic agent and genetic material that can be applied locally for cervical cancer. Cervical cancer is one of the most life-threatening types of cancer among women and is generally resistant to chemotherapy. Paclitaxel has been selected as chemotherapeutic agent, and siRNA that inhibits the Bcl-2 oncogene has been selected as the genetic material for simultaneous vaginal delivery. For this purpose, three different solid lipid nanoparticles (SLNs) were prepared that include Bcl-2 siRNA and paclitaxel and paclitaxel/Bcl-2 siRNA combination separately, and these SLN formulations were dispersed in vaginal suppositories prepared with PEG 6000. First, the physicochemical properties of SLNs, their cytotoxicities on HeLa cell lines, and the transfection ability of siRNA-incorporated SLN on the cells have been examined. Afterward, the release of SLNs from the three different vaginal suppositories prepared has been determined via horizontal diffusion chamber system. The loaded amount to the SLNs and release amount from suppositories of paclitaxel have been determined via HPLC, whereas stability, loading, and release amount of siRNA has been determined via gel retardation system and UV spectrophotometer.

Keywords

Bcl-2 siRNA Paclitaxel Cationic SLN Vaginal suppository 

References

  1. 1.
    Urasa M, Darj E (2011) Knowledge of cervical cancer and screening practices of nurses at a regional hospital in Tanzania. Afr Health Sci 11(1):48–57PubMedPubMedCentralGoogle Scholar
  2. 2.
    Volodko V, Gordon M, Salla M, Ghazaleh HA, Baksh S (2014) RASSF tumor suppressor gene family: biological functions and regulation. FEBS Lett 588:2671–2684CrossRefPubMedGoogle Scholar
  3. 3.
    Zhang S, Zhao B, Jiang H, Wang B, Ma B (2007) Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release 123:1–10CrossRefPubMedGoogle Scholar
  4. 4.
    Xu C, Wang J (2015) Delivery systems for siRNA drug development in cancer therapy. Asian J Pharm Sci 10:1–12CrossRefGoogle Scholar
  5. 5.
    Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Tseng YC, Mozumdar S, Huang L (2009) Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 61:721–731CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH (2006) Delivery of RNA interference. Cell Cycle 5(18):2103–2109CrossRefPubMedGoogle Scholar
  8. 8.
    Takabatake Y, Isaka Y, Mizui M, Kawachi H, Takahara S, Imai E (2007) Chemically modified siRNA prolonged RNA interference in renal disease. Biochem Biophys Res Commun 363(2):432–437CrossRefPubMedGoogle Scholar
  9. 9.
    Gary D, Puri N, Won YY (2007) Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 121:64–73CrossRefPubMedGoogle Scholar
  10. 10.
    Reischl D, Zimmer A (2009) Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomed Nanotechnol Biol Med 5(1):8–20CrossRefGoogle Scholar
  11. 11.
    Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS (2007) Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. VisionRes 47(9):1202–1208Google Scholar
  12. 12.
    Chen GX, Dong QH, Zhang JW, Fu FF, Xu ZF, Liang QY, Zheng S, Ding JY (2006) Knockdown of PLK1 mRNA by special siRNA. Yi Chuan 28(1):21–25PubMedGoogle Scholar
  13. 13.
    Sioud M, Sørensen DR (2003) Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 312(4):1220–1225CrossRefPubMedGoogle Scholar
  14. 14.
    Bouxsein NF, Mcallister CS, Ewert KK, Samuel CE, Safinya RC (2007) Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA. Biochemistry 46(16):4785–4792CrossRefPubMedGoogle Scholar
  15. 15.
    Kataoka K, Itaka K, Nishiyama N, Yamasaki Y, Oishi M, Nagasaki Y (2005) Smart polymeric micelles as nanocarriers for oligonucleotides and siRNA delivery. Nucleic Acids Symp Ser 49(1):17–18CrossRefGoogle Scholar
  16. 16.
    Katas H, Alpar HO (2006) Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 115(2):16–25CrossRefGoogle Scholar
  17. 17.
    Savaese A, Cognetti F (2003) New drugs in the treatment of recurrent or metastatic cervical cancer. Crit Rev Oncol Hematol 48:323–327CrossRefGoogle Scholar
  18. 18.
    Wu J, Liu Q, Lee RJ (2006) A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm 316:148–153CrossRefPubMedGoogle Scholar
  19. 19.
    Thu TH, Dass CR, Dunstan DE (2008) Injectable chitosan hydrogels for localized cancer therapy. J Control Release 126:205–216CrossRefGoogle Scholar
  20. 20.
    Chimmiri P, Rajalakshmi R, Mahitha B, Ramesh G, Noor Ahmed VH (2012) Solid lipid nanoparticles: a novel carrier for cancer therapy. Int J Pharm Biol Sci 3(3):405–413Google Scholar
  21. 21.
    Serpea L, Catalano MG, Cavalli R, Ugazio E, Bosco O, Canaparo R, Muntoni E, Frairia R, Gasco MR, Eandi M, Zara GP (2004) Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 58:673–680CrossRefGoogle Scholar
  22. 22.
    Shah R, Eldridge D, Palombo E, Harding I (2014) Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J Phys Sci 25(1):59–75Google Scholar
  23. 23.
    Banerjee I, De K, Mukherjee D, Dey D, Chattopadhyay S, Mukherjee M, Mandal M, Bandyopadhyay AK, Gupta A, Ganguly S, Misra M (2016) Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced antiangiogenic and anti-glioma therapy. Acta Biomater 38:69–81CrossRefPubMedGoogle Scholar
  24. 24.
    Yu YH, Kim E, Park DE, Shim G, Lee S, Kim YB, Kim CW, Oha YK (2012) Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm 80:268–273CrossRefPubMedGoogle Scholar
  25. 25.
    Pavelić Z, Skalko-Basnet N, Filipović-Grcić J, Martinac A, Jalsenjak I (2005) Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J Control Release 106:34–43CrossRefPubMedGoogle Scholar
  26. 26.
    Hussain A, Ahsan F (2005) The vagina as a route for systemic drug delivery. J Control Release 103:301–313CrossRefPubMedGoogle Scholar
  27. 27.
    Dobaria N, Mashru R, Vadia NH (2007) Vaginal drug delivery systems: a review of current status. East Cent Afr J Pharm Sci 10:3–13Google Scholar
  28. 28.
    Choudhury A, Das S, Kar M (2011) A review on novelty and potentiality of vaginal drug delivery. Int J PharmTech Res 3(2):1033–1044Google Scholar
  29. 29.
    Haas S, Woerdenbag H, Sznitowska M (2015) Rectal and vaginal. In: Bouwman-Boer Y, Fenton-May V, Brun PL (eds) Practical pharmaceutics: an international guideline for the preparation, care and use of medicinal products. Springer International Publishing AG, Cham, pp 190–225Google Scholar
  30. 30.
    Büyükköroğlu G, Şenel B, Başaran E, Yenilmez E, Yazan Y (2016) Preparation and in vitro evaluation of vaginal formulations including siRNA and paclitaxel-loaded SLNs for cervical cancer. Eur J Pharm Biopharm 109:174–183CrossRefPubMedGoogle Scholar
  31. 31.
    Büyükköroğlu G, Yazan EY, Öner AF (2015) Preparation and physicochemical characterizations of solid lipid nanoparticles containing DOTAP® for DNA delivery. Turk J Chem 39:1012–1024CrossRefGoogle Scholar
  32. 32.
    Gvili K, Benny O, Danino D, Machluf M (2006) Poly(D,L-lactide-coglycolide acid) nanoparticles for DNA delivery: waiving preparation complexity and increasing efficiency. Biopolymers 85:379–391Google Scholar
  33. 33.
    Mehnert W, Mäder K (2001) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47(2–3):165–196CrossRefPubMedGoogle Scholar
  34. 34.
    Şenel B, Büyükköroğlu G, Yazan Y (2015) Solid lipid and chitosan particulate systems for delivery of siRNA. Pharmazie 8:698–705Google Scholar
  35. 35.
    Neves J, Amaral MH, Bahia MF (2008) Performance of an in vitro mucoadhesion testing method for vaginal semisolids: influence of different testing conditions and instrumental parameters. Eur J Pharm Biopharm 69:622–632CrossRefPubMedGoogle Scholar
  36. 36.
    Owen DH, Katz DF (1999) A vaginal fluid simulant. Contraception 59:91–95CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Gülay Büyükköroğlu
    • 1
    Email author
  • Behiye Şenel
    • 1
  • Evrim Yenilmez
    • 2
  1. 1.Department of Pharmaceutical Biotechnology, Faculty of PharmacyAnadolu UniversityEskisehirTurkey
  2. 2.Department of Pharmaceutical Technology, Faculty of PharmacyAnadolu UniversityEskisehirTurkey

Personalised recommendations